PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Higher upside than AXSM's upside of 56.00%.
Buy
Equal to AXSM's analyst recommendation of Buy.
Analyze analyst forecasts for the company and compare them with competitors.
1.17M
No peer data available for comparison.
-234.73K
No peer data available for comparison.
-1.16
No peer data available for comparison.
-30.77M
No peer data available for comparison.
-234.73K
No peer data available for comparison.
43.49M
No peer data available for comparison.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than AXSM's revenue growth rate of 25.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than AXSM's ebitda margin of 23.37%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than AXSM's ebit margin of 22.87%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to AXSM's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than AXSM's receivables as percentage of revenue of 82.08%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than AXSM's inventories as percentage of revenue of 62.85%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than AXSM's payables as percentage of revenue of 78.44%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than AXSM's capex as percentage of revenue of -0.32%.
4.99%
Better than AXSM's weighted average cost of capital (wacc) of 9.92%.
5.02%
Better than AXSM's cost of equity of 10.17%.
4.08%
Better than AXSM's cost of debt of 4.26%.
-0.23
Better than AXSM's beta of 1.25.
30.07M
Better than AXSM's diluted shares outstanding of 45.43M.
1.57M
Better than AXSM's total debt of 186.37M.
49.31M
Worse than AXSM's total equity of 4.18B.
50.89M
Worse than AXSM's total capital of 4.36B.
3.09%
Better than AXSM's debt weighting of 4.27%.
96.91%
Better than AXSM's equity weighting of 95.73%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to AXSM's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than AXSM's net debt of -199.82M.
71.33M
Worse than AXSM's equity value of 6.33B.
2.37
Worse than AXSM's equity value per share of 139.31.